Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Tildrakizumab in Psoriatic Arthritis
2022-501480-41-00Phase 3Authorised
- Sponsor
- Sun Pharma
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of risankizumab in psoriatic arthritis (PsA), sponsored by Sun Pharma. Primary endpoints: Safety - Incidence and intensity of adverse events, Efficacy - ACR20 response and 2 more. Planned start Feb 2023; status: authorised.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2022-501480-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501480-41-00.